文献速递妇科

卵巢癌中HER2的预后意义:与同源重组缺陷及叶酸受体α表达的关联

Prognostic implications of HER2 in ovarian cancer: Associations with homologous recombination deficiency and folate receptor alpha expression.
PubMed 文献 · Gynecol Oncol · 2025-11-04

在Yonsei癌症中心回顾性分析441例原发或复发卵巢癌患者的HER2免疫组化,HER2 2+/3+占23.6%,在黏液性(50.0%)和透明细胞癌(51.2%)中更常见;在211例HGSC且已知HRD状态患者中,HER2 2+/3+在HRD组(21.6%)较HRP组(6.9%)更常见;HER2 2+/3+与总体OS较差相关,在HRD HGSC中更差;78例有连续HER2数据者中34.6%在进展时评分升高,与OS较差趋势相关;可评估病例中9.4%同时HER2 2+/3+且FRα高表达。

要点

  • HER2 2+/3+在卵巢癌中占23.6%,黏液性和透明细胞癌中更常见。
  • HGSC中HER2 2+/3+在HRD组(21.6%)较HRP组(6.9%)更常见。
  • HER2 2+/3+与总体OS较差相关,在HRD HGSC中更差;34.6%进展时评分升高与OS较差趋势相关。

核心结论

  • HER2过表达在卵巢癌中相对常见,在BRCA1/2突变/HRD以及黏液性或透明细胞卵巢癌中具有预后相关性。
  • 需要进一步临床试验以优化HER2和FRα靶向抗体偶联药物在这些人群中的使用。

研究设计与样本

  • 回顾性分析441例在Yonsei癌症中心接受HER2免疫组化的原发或复发卵巢癌患者。

主要发现

  • 104例(23.6%)为HER2 2+/3+,在黏液性癌(50.0%)和透明细胞癌(51.2%)中更常见。
  • 在211例HGSC且已知HRD状态患者中,HER2 2+/3+在HRD组(21.6%)较HRP组(6.9%)更常见。
  • HER2 2+/3+肿瘤与总体OS较差相关,在HRD HGSC中结局更差。
  • 78例有连续HER2数据患者中,34.6%在进展时评分升高,与OS较差趋势相关。
  • 可评估病例中9.4%同时为HER2 2+/3+且FRα高表达。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We evaluated expression patterns of human epidermal growth factor receptor 2 (HER2) by histological subtype and key biomarkers in ovarian cancer (OC). METHODS: We retrospectively analyzed 441 patients with primary or recurrent OC who underwent HER2 immunohistochemistry (IHC) at Yonsei Cancer Center. Association between histological subtype, HER2 and folate receptor alpha (FRα) expression, BRCA1/2 mutation or homologous recombination deficiency (HRD) status, and overall survival (OS) were evaluated. RESULTS: HER2 2+/3+ were found in 104 patients (23.6 %), more frequent in mucinous (50.0 %) and clear cell carcinomas (51.2 %). Among 211 patients with high-grade serous carcinoma (HGSC) and known HRD status, HER2 2+/3+ tumors were more common in HRD (21.6 %) than in homologous recombination proficient (HRP) (6.9 %) patients. HER2 2+/3+ tumors were associated with poorer OS overall, with worse outcomes in HRD HGSC. Of 78 patients with sequential HER2 data, 34.6 % showed increased score during progression, correlating with a trend toward poorer OS. Concurrent HER2 2+/3+ and high FRα expression was observed in 9.4 % of evaluable cases. CONCLUSIONS: HER2 overexpression is relatively common and had prognostically relevant in BRCA1/2-mutated/HRD and in mucinous or clear cell OC. Further clinical trials are warranted to optimize use of HER2- and FRα-targeted ADCs in these group.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Park J, Lee D, Kim S, et al. Prognostic implications of HER2 in ovarian cancer: Associations with homologous recombination deficiency and folate receptor alpha expression. Gynecol Oncol. 2025. PMID: 41192265. doi:10.1016/j.ygyno.2025.10.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。